COMMENT| VOLUME 399, ISSUE 10325, P609-610, FEBRUARY 12, 2022 Another piece in the COVID-19 treatment puzzle Cristina Mussini, Alessandro Cozzi-Lepri Lancet 2022; 399: 609-610 DOI:https://doi.org/10.1016/S0140-6736(22)00154-4 A new study1 from the RECOVERY Collaborative Group adds another piece to the puzzle of severe COVID-19 therapy. The RECOVERY trials have been pivotal in providing evidence on the efficacy of compounds within current trea...

Application of Artificial Intelligence in the ICU Artificial Intelligence (AI) holds great promise in critical care. Vast amounts of data are regularly collected in intensive care units, making ICUs the perfect environment for deploying machine-learning techniques. AI in ICUs can have several applications. For example, when determining the short and long-term outcomes of different interventions, a well-designed ICU system could provide significant support in the...

Original Investigation January 18, 2022 Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial Jeffrey S. Berger, Lucy Z. Kornblith, Michelle N. Gong, et al JAMA. 2022;327(3):227-236. doi:10.1001/jama.2021.23605 Abstract Importance  Platelets represent a potential therapeutic target for improved clinical...

COMMENT|ONLINE FIRST Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 Adrienne E Shapiro, Rachel A Bender Ignacio Lancet Infect Dis Published:December 23, 2021 DOI:https://doi.org/10.1016/S1473-3099(21)00762-3 The research community has responded to the COVID-19 pandemic with innovative platform trials to address the need for rapid evaluation of novel agents using a common protocol, among them being RECOVERY,1&nbs...

ARTICLES|ONLINE FIRST Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 COVID-19 National Preparedness Collaborators Lancet Published:February 01, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00172-6 Summary Background National rates of COVID-19 infection and fatality have varied dramatically since the o...

2030: Projections for the Emergency Medicine Physician Workforce Over the last few decades, the emergency physician workforce has undergone a dramatic transformation. There was a time when most physicians working in the emergency department had not completed residency training in emergency medicine. This began around 1970. Today, there are 273 emergency medicine residences accredited by the Accreditation Council for Graduation Medical Education (ACGME). While em...

ARTICLES|ONLINE FIRST Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group Lancet Infect Dis Published:December 23, 2021DOI:https://doi.org/10.1016/S1473-3099(21)00751-9 Summary Background We aimed to assess the efficacy and safety of two neutralising mono...

ARTICLES| VOLUME 399, ISSUE 10325, P665-676, FEBRUARY 12, 2022 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet 2022; 399: 665-676 Summary Background Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, ...

ICU Management & Practice, Volume 21 - Issue 3, 2021 Oxygen Therapy in COVID-19 Patients: The Role of HFNC and CPAP Oxygen therapy and mechanical ventilation in patients with COVID-19 and steps to choose the right therapeutic strategy for each patient. Introduction Severe acute respiratory syndrome coronavirus CoV-2 is the highly contagious viral agent responsible for the ongoing COVID-19 pandemic. COVID-19 is the name of the syndrome caused by SARS-C...

ARTICLES|ONLINE FIRST Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis Manoj V Maddali, Matthew Churpek, Tai Pham, et al Lancet Respir Med Published:January 10, 2022DOI:https://doi.org/10.1016/S2213-2600(21)00461-6 Summary Background Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct...